Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lilly's Mounjaro and Zepbound appear to have an efficacy advantage over Novo Nordisk's Ozempic and Wegovy. Lilly also has a stronger product lineup and pipeline outside of the diabetes and obesity indications than Novo Nordisk.

Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?

CRISPR Therapeutics

Intuitive Surgical

Pfizer

Vertex Pharmaceuticals

Now is a great time to consider stocks that may boost your portfolio, both in the new investing year and over time. Companies offering steady earnings growth -- or the promise of earnings growth -- are a good place to start.

5 Top Stocks to Buy Before 2024

Eli Lilly said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca, which is used to treat a form of blood cancer.

US FDA gives second approval to Eli Lilly's drug for type of blood cancer

The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, achieved an overall response rate of 72%  INDIANAPOLIS , Dec. 1, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor. Jaypirca was approved under the FDA's Accelerated Approval pathway based on overall response rate (ORR) and duration of response (DOR) from the open-label, single-arm, multicohort, international, Phase 1/2 BRUIN trial.1 Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 Jaypirca, the first and only FDA-approved non-covalent (reversible) BTK inhibitor, is a highly selective kinase inhibitor that can extend the benefit of targeting the BTK pathway in CLL/SLL patients previously treated with a covalent BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib) and a BCL-2 inhibitor.1,2 Jaypirca utilizes a novel binding mechanism and has the largest body of evidence of any targeted therapy in patients previously treated with a BTK inhibitor.1,2 "Once patients with CLL or SLL have progressed on covalent BTK inhibitor and BCL-2 inhibitor therapies, treatments are limited and outcomes can be poor, making the approval of Jaypirca a meaningful advance and much-needed new treatment option for these patients," said William G.

Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor

The shares have vaulted as a result of its recently approved weight-loss drug. But it also pays a dividend, which has increased steadily over the years.

1 Underrated Reason to Buy Eli Lilly Stock

Some leading U.S. obesity specialists say they expect Eli Lilly's powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk's popular Wegovy as they belong to the same class of medicines. The views of the five doctors, all senior physicians practicing obesity medicine at top universities and hospitals, indicate that Novo's drug is not likely to have a significant edge based on its heart benefits, even though it will be years before Lilly produces similar cardiovascular data.

US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy

Bunge Global SA

Baker Hughes Co

Estee Lauder

Las Vegas Sands

NIKE

Skyworks Solutions

Teleflex

Investors can only hope stocks do as well in December as they did in November. There are definitely some S&P 500 stocks that glisten.

December Looks Great For Investors Who Own 9 Stocks

Novo Nordisk

Eli Lilly (NYSE: LLY) and Novo Nordisk NYSE: NVO) stock prices have been some of the hottest names in Wall Street. NVO has soared by over 48% this year while LLY has surged by over 61%.

Eli Lilly, Novo Nordisk to benefit as Pfizer's weight loss drug implodes

Eli Lilly and Novo Nordisk, riding the wave of enthusiasm for obesity meds, are seeing their stock prices soar. But behind them are coming new therapies from companies for investors that are drawn to the size of the obesity market but put off by the valuations.

Worried About a Weight-Loss Stock Bubble? Here Are Some Alternatives.

Verve Therapeutics

Verve Therapeutics is focused on developing in vivo gene editing therapies for cardiovascular disease. The company aims to disrupt the chronic care model for CVD by targeting genes related to atherosclerotic cardiovascular disease. Verve's interim data from its phase 1b clinical trial showed promising efficacy in reducing LDL-C, but safety concerns caused a sell-off in its stock.

Verve Therapeutics: Lilly's Experience A Welcome Addition To In Vivo Gene Therapy Program

A large analysis of electronic health records shows a strong advantage for Eli Lilly's weight management treatment tirzepatide. Patients given tirzepatide were more than twice as likely to achieve a 15% weight reduction as patients treated with Ozempic.

Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?

AbbVie

Johnson & Johnson

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

4 Large Drug Stocks to Watch as IBD Market Gains Traction

Arecor Therapeutics PLC (AIM:AREC) announces an expanded collaboration with Eli Lilly and Company that will see the former's Arestat technology use to develop a new enhanced liquid formulation of an unnamed product sold by the American drugs giant. Lilly will finance the development and holds an option to acquire rights to this innovative formulation and related intellectual property.

Arecor extends its relationship with Lilly as it inks another technology deal

Eli Lilly and Company (NYSE:LLY ) 6th Evercore ISI HealthCONx Conference November 28, 2023 3:50 PM ET Company Participants Dan Skovronsky - EVP, Chief Scientific and Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Michael DiFiore - Evercore ISI Umer Raffat Pleasure to have management team from Eli Lilly. There's a ton to go through.

Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript)

Novartis

Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.

3 Large Drug Stocks That Have Outperformed Industry YTD

Novo Nordisk stock skidded Tuesday after Eli Lilly's weight-loss drug outperformed Novo's rival medication in a first-of-its-kind study.

Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives

Scheduled to open in the first half of 2024, Lilly's new Gateway Labs location, in partnership with Alexandria Real Estate Equities, will feature a world-class, state-of-the-art lab facility to support early-stage scientific entrepreneurs and companies  INDIANAPOLIS , Nov. 28, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in the first half of 2024.

Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego

Alexandria Real Estate Equities

Alexandria and Lilly, which began their strategic relationship in 2008, are collaborating to support and accelerate the development of promising early-stage companies in the growing San Diego life science ecosystem PASADENA, Calif. , Nov. 28, 2023 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science, agtech and advanced technology mega campuses in AAA innovation cluster locations, today announced an exclusive partnership with longstanding tenant Eli Lilly and Company (NYSE: LLY) to expand Lilly's innovative Gateway Labs model to the San Diego life science cluster.

Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego

Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's Mounjaro than those taking Novo Nordisk's popular rival weight loss drug, according to an analysis of health records and other data.

Lilly's Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis finds

Eli Lilly and Co (NYSE:LLY)'s diabetes drug Mounjaro is more effective for weight loss than Novo Nordisk (NYSE:NVO)'s Ozempic in overweight or obese adults, a real-world analysis by Truveta Research reveals. Patients on Mounjaro showed significantly higher chances of losing 5%, 10%, and 15% of body weight over three months, six months, and a year compared to those on Ozempic.

Mounjaro outperforms Ozempic for weight loss in adults, study says

Mounjaro – a popular treatment for diabetes is more effective for losing weight than Ozempic, as per a large study of real-word data by Truveta Research.

Mounjaro is more effective for weight loss than Ozempic: study reveals

Diabetes-turned-weight loss drug Mounjaro is more effective for shedding off extra pounds than its ultra-popular counterpart, Ozempic, according to a new study.

Ozempic is not the most effective weight-loss drug on the market: study

Eli Lilly's Mounjaro is significantly more effective than Novo Nordisk's Ozempic in producing weight loss in patients with overweight or obesity, a new real-world study found.

Eli Lilly's Mounjaro three times more effective than Ozempic for weight loss, real-world study finds

Apple

Amazon

Broadcom

Alphabet

Microsoft

NVIDIA

Tesla

UnitedHealth Group

Exxon Mobil

For years now, a significant cohort of investors gravitated towards the allure of the S&P 500 index over individual stocks.

Investing $10K in S&P 500 buys this much of largest stocks

Carnival

Investors should select a variety of companies with strong earnings prospects and hold on for a number of years. It's a great idea to include companies with a track record of success and leadership in their markets.

News for Eli Lilly Stock (LLY)